Murphy BL, et al. - Researchers assessed the trend of neoadjuvant chemotherapy (NAC) use over time by biological subtype of breast cancer. Analysis of all patients with invasive breast cancer who underwent curative intent surgery and were treated with chemotherapy from 2010 to 2015 from the National Cancer Database was performed. Findings suggest that among all biologic subtypes, receipt of chemotherapy in the neoadjuvant setting has been increasing. In TNBC and human epidermal growth factor receptor 2-positive (HER2+) disease, the highest use of NAC was noted. The use in these subgroups was twice as frequent as in hormone receptor (HR)+/HER2- disease.